Teva Finally Puts a Number on Mylan Deal, Investors Stand to Profit

Teva is a 114-year old maker of pharmaceutical generics, and they've generated lots of cash along the way. They've been coy about their intention to purchase Mylan, but now there's a healthy number on the table, and share prices are on the way up... Watch Video Tags: how to invest , mylan , Stocks , teva , teva mylan deal To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post Teva Finally Puts a Number on Mylan Deal, Investors Stand to Profit appeared first on Money Morning - We Make Investing Profitable .